Several key market insights have surfaced regarding Biogen Inc. LSV Asset Management has reportedly expanded its position, and Wedbush has increased their price target from $178 to $187 for the biotech giant. Furthermore, Truist Securities and Wells Fargo have also raised their Biogen price targets. A notable surge has been observed in Biogen's stock, partially attributed to the momentum from its exciting new drugs like Leqembi. Maria Freire has been announced as the company's new chair, effective June 2026. Biogen's Q4 results surprisingly beat expectations with the help of one key drug. Additionally, Biogen's FY25 earnings show stable EPS despite pressure from its Multiple Sclerosis Franchise. However, concerns persist regarding the company's debt levels and recent share price recovery. Excitingly, the firm has received priority review in China for Leqembi and has also been awarded FDA’s breakthrough tag for litifilimab. Looking forward, it seems that the company is refocusing on high-need neurology as new drugs reach significant development milestones.
Biogen BIIB News Analytics from Mon, 21 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 10:52:46 GMT - Rating 6 - Innovation 4 - Information 7 - Rumor 2
